Consensus Neumora Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
9.45 ^USD	-2.48%		-1.36%	-44.57%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

c9605f5.Rp4ViTqpbiczQiy7W8eGCZ04ebgzaLkHElX5WzKrHyE.Ec1X_2D5OW9cOlrcHfC2WtpZKJVmDf1DYmLNOV7-VUR15HfZcMFXfkA3aQ~c30310e53ab00b88a37b41dc1498b254

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	Mar. 08	MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target	Dec. 12	MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target	23-10-10	MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating	23-10-10	MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder	23-10-10	MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target	23-10-10	MT
William Blair Starts Neumora Therapeutics With Outperform Rating	23-10-10	MT
BofA Securities Starts Neumora Therapeutics With Buy Rating	23-10-10	MT
Stifel Starts Neumora Therapeutics at Buy	23-10-10	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.45 USD

Average target price

23.84 USD

Spread / Average Target

+152.29%

High Price Target

29 USD

Spread / Highest target

+206.88%

Low Price Target

18 USD

Spread / Lowest Target

+90.48%